Overview

An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.

Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
A Phase 1 Study of AGENT-797 to treat moderate to severe acute respiratory syndrome in COVID-19 patients.
Phase:
Phase 1
Details
Lead Sponsor:
AgenTus Therapeutics, Inc.
MiNK Therapeutics